Zobrazeno 1 - 8
of 8
pro vyhledávání: ''
Autor:
Aditi Jain, Vibha Rani
Publikováno v:
Life Sciences. 205:97-106
Aim Doxorubicin (Dox) is one of the most cardiotoxic anti-cancerous drug that is widely used for broad-range of cancers. There is an urgent need for developing cardio-oncological therapeutic interventions. Natural products having both anti-cancerous
Autor:
Mingyong Xie, Zi-Wei Shi, Yu-Xin Yan, Ming Chen, Wen-Juan Li, Yu-Fei Yao, Xiang Liu, Le-Feng Wang
Publikováno v:
Life Sciences. 180:151-159
Aims (−)-Epigallocatechin-3-gallate (EGCG), a major green tea polyphenol compound, plays an important role in the prevention of cardiovascular disease and cancer. The present study aimed to investigate the effects of EGCG on doxorubicin (DOX)-induc
Publikováno v:
Life Sciences. 178:1-8
Doxorubicin (DOX) is one of the most commonly used and effective chemotherapeutic agents. Despite its clinical benefits, the use of DOX is often limited by serious adverse effects, such as severe cardiotoxicity and myelosuppression. Recent progress i
Autor:
Alireza Mohajjel Nayebi, Javad Ashrafi Helan, Yadollah Azarmi, Gholamreza Assadnassab, N. Razmaraii, Hossein Babaei
Publikováno v:
Life Sciences. 157:145-151
Doxorubicin (DOX)-induced cardiotoxicity is well-known as a serious complication of chemotherapy in patients with cancer. It is unknown whether crocin (CRO), main component of Crocus sativus L. (Saffron), could reduce the severity of DOX-induced card
Autor:
Madhusudana Kuncha, Bidya Dhar Sahu, Ragampeta Srinivas, Ramakrishna Sistla, Jerald Mahesh Kumar, Roshan M. Borkar
Publikováno v:
Life Sciences. 144:8-18
Aims Doxorubicin is a widely used anthracycline derivative anticancer drug. Unfortunately, the clinical use of doxorubicin has the serious drawback of cardiotoxicity. In this study, we investigated whether baicalein, a bioflavonoid, can prevent doxor
Autor:
Zhen Huang, Heping Gu, Rui Yao, Hongrui Chen, Junhui Xing, Cui Liang, Zhe Meng, Yapeng Li, Yanzhou Zhang, Lu Gao, Ling Li, Yuan Liu, Sen Guo, Yuzhou Liu
Publikováno v:
Life sciences. 207
Aims The clinical use of doxorubicin (Dox) is limited due to a degenerative irreversible cardiac toxicity, but the precise mechanisms that contribute to this pathological response are not understood. C1q/TNF-related protein 1 (CTRP1), which is a cons
Autor:
Farahnaz Jazaeri, Amir Hossein Abdolghaffari, Mina Khalilzadeh, Alireza Abdollahi, Farhad Abdolahi, Ahmad Reza Dehpour
Publikováno v:
Life sciences. 207
Aims Clinical use of doxorubicin, an effective chemotherapeutic agent, has limited uses due to dose-dependent cardiac toxicity. It has been supposed that the production of free radicals and calcium ions overload can lead to cardiac toxicity. Magnesiu
Autor:
Thomas Nesakumar Jebakumar Immanuel Edison, Bharath Kumar Velmurugan, Arivalagan Pugazhendhi, Joe Antony Jacob, Indira Karuppusamy
Publikováno v:
Life sciences. 200
Doxorubicin (Dox) is a valuable anticancer drug for hematologic and solid tumors. Yet, it can cause multi-organ toxicities in various patients. Since toxicity evaluation is a major criterion to discuss for every experiment, the current mini-review fo